Ignite Creation Date:
2025-12-24 @ 6:44 PM
Ignite Modification Date:
2026-02-24 @ 2:07 PM
Study NCT ID:
NCT00522457
Status:
TERMINATED
Last Update Posted:
2011-04-29
First Post:
2007-08-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
Sponsor:
Neovii Biotech
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
IV-ERT-BC-04
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Manager of Regulatory Affairs
Old Organization:
Fresenius Biotech North America
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |